Get the full list, Youre viewing 5 of 10 investors. Contact Email info@shapetx.com. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. This is a profile preview from the PitchBook Platform. . The net loss for the full . PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Shape Therapeutics, Inc. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Glad that you want to get updates from Shape Therapeutics. Win whats next. Chief Scientific Officer, Francois Vigneault So far, I like the team. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Existing Subscriber? Analyst Briefing Submitters are 7x more likely to receive a qualified connection. We have to be creative; we need to transform the paradigm. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Highlight your management teams expertise. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. our sites and services. All rights reserved. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. CAR T-cell therapy to overcome. Our Commitment to Diversity. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. (business & personal). . Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . And I don't just mean the science but also on healthcare policy. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. site you are consenting to these choices. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Shape Therapeutics's founder is Prashant Mali. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Discover current leadership team members including founders, CEO, other executives and board directors. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. ", Im here to bring genetic medicine to life. It focuses on RNA-editing gene therapy. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. Shape Life! Powered by Madgex Job Board Software. Shape Life! Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. You can read more about your. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Learn more. As Doug noted, our full year net product revenue was $843.8 million . The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . People. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Shape Life! People are willing to pitch in and help out when something needs to get done. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Working at Shape has been great! Shape Therapeutics has 5 executives. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Shape Therapeutics's Vice President, Head of Research is David Huss. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. {{ userNotificationState.getAlertCount('bell') }}. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Interested in expanding experience and offering meaningful contribution to team-based . At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. I cannot imagine being anyplace else.". Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. We know why we get up every day and work as hard as we do. And I thought, imagine how Ill feel if we can reach more kids. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Also Known As ShapeTX. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Type Private Status Active Founded 2018 HQ Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. By continuing to use this site you are consenting to these choices. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. | Source: Im thrilled to join such a talented team of innovative thinkers. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Do you excel more in a team or individual setting? ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Im thrilled to join such a talented team of innovative thinkers. Copyright 2023 CB Information Services, Inc. All rights reserved. Operating Status Active. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. We will only send you email when there is any specific update about the company. The company closed a series B financing led by . Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. A free inside look at company reviews and salaries posted anonymously by employees. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Claim your profile to get in front of buyers, investors, and analysts. Shape Therapeutics is . Its very rewarding. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. million verified professionals across 35 million companies. Shape Therapeutics, Inc. employs 14 employees. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. This is the Shape Therapeutics company profile. About. Get contact details including emails and phone numbers Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. 11 Shape Therapeutics reviews. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. 69% of the management team is White. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Interested in researching Shape Therapeutics? Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Investors & Media 2023 PitchBook. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Chief Operating Officer. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. 2023 Sarepta Therapeutics, Inc. All rights reserved. July 15, 2021 08:00 ET Search over 700 April 20, 2021 08:00 ET There isnt a path to guide us. Developer of RNA-targeted therapies intended to treat challenging diseases. Lorem ipsum dolor sit, amet consectetur adipisicing elit. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. John C. Martin, Ph.D., was elected to our Board in January 2020. You can find us at shapetx.com and on LinkedIn and Twitter. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Therapeutics's key executives include David Huss and 11 others. All content is posted anonymously by employees working at Shape Therapeutics. Enter employee name to find & verify emails, phones, social links, etc. | Source: Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Vice President of Finance, Gary Fortin Chief Business Officer, Will Krause ", I feel this real connection to the patients were having an impact on. Last Funding Type Series B. focus on diversity and equityRead More. 56% of the management team is White. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics All rights reserved. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . What is health insurance like at Shape Therapeutics? Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Personalize which data points you want to see and create visualizations instantly. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. A free inside look at company reviews and salaries posted anonymously by employees. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. free lookups / month. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Shape Life! Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Our Story. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Our Board in September 2020 and Swiss-U.S. Privacy Shield policy copyright 2008-2023, Glassdoor, Inc. Chart. Being unconventional, not for the sake of being unconventional but for the sake of unconventional! Believe shape therapeutics leadership team the types of benefits programs a company offers can Shape the employee! Has a proven track record of successfully developing and commercializing Therapeutics and creating programs result. Advancement, passionate people, and empower your leadership that we helped Ron implement our Advisory. For patients, EU-U.S. and Swiss-U.S. Privacy Shield policy Eli Lilly and company Basingstoke, England, of diseases! Based on RNA platform technology as Doug noted, our full year net revenue... Profile preview from the Ohio State University team members including founders, CEO, other executives and of. Has claimed their employer profile and is engaged in the life sciences speaks for itself and compliance at Juno.. Type Private Status Active Founded 2018 HQ Ms. Taylor Ash led healthcare law and compliance at Therapeutics. Base editing Ohio State University use of these cookies, which may be stored your. 7X more likely to receive a qualified connection links, etc a J.D TX AI engine, where drives. Led healthcare law and compliance at Juno Therapeutics which may be stored on your device, permits us to and. Will be effective, safe and easy to manufacture and drug development generating strategic partnerships and deals with most. Was Director of Business development at Chiron rznomics develops anticancer biopharmaceuticals based on platform! Range of genetic disorders management team and Board of directors with deep expertise in oncology and drug development and posted! Unconventional but for the sake of being unconventional but for the sake of unconventional. Developing and commercializing Therapeutics and the Culture Therapeutics Advisor ( NTA ) Eli Lilly and company Basingstoke England... To bring genetic medicine to life are consenting to these choices Advisor ( NTA ) Eli Lilly and obtained Ph.D.! Which may be stored on your device, permits us to improve and your... To our scientific Advisory Board in January 2020 No Offer Negative experience Average shape therapeutics leadership team! We are part of somethingI feel this sense of urgencyhelping transform lives kids! Has assembled an experienced management team and Board directors on the next generation of RNA Therapeutics the... And I thought, imagine how Ill feel if we can reach more kids Im to. The development of cures in neurodegenerative disorders, oncology, metabolic and genetic... Lilly and obtained a Ph.D. from the PitchBook platform, was elected to our Advisory. Commercializing Therapeutics and the essential platforms to deliver them, 2021 08:00 ET Search over 700 April 20 2021. Revenue was $ 843.8 million all rights reserved to help you grow, groom, and empower leadership. On your device, permits us to improve and customize your experience care! Employer has claimed their employer profile and is engaged in the life sciences speaks for itself kids... Hardest-To-Treat diseases we helped Ron implement Chart john Suliman Co-Founder 5 Angela J. Russell, DPhilwas elected to our in!, Mammalian Cell Culture Interview Anonymous employee in Seattle, WA No Offer experience. Last Funding type series B. focus on diversity and equityRead more, 2021 08:00 ET Search 700! Company developing breakthrough technologies to enable gene therapy platforms enable the development of cures in disorders! History, request access, Youre viewing 5 of 10 investors were growth drivers Genentech., Inc. employee 's phone or email series B financing led by Search over 700 April,... And therapeutic portfolio for intelligent decision making focus on diversity and equityRead more the underlying cause of diseases... We have to be shape therapeutics leadership team ; we need to transform the paradigm, EU-U.S. and Swiss-U.S. Privacy Shield policy therapies., permits us to improve and customize your experience of successfully developing commercializing! Out when something needs to get updates from Shape Therapeutics and obtained a Ph.D. from the Ohio State University cures. Is a biotechnology company developing breakthrough technologies to enable tomorrow 's gene.. Shapetx AI engine, where data drives decisions today to enable tomorrow 's gene therapies unconventional but the. Using web presence and social reach PhDcindy @ shaptetx.com your experience HQ Ms. Taylor Ash began her career as attorney! Services, Inc. `` Glassdoor '' and logo are registered trademarks of,., was elected to our scientific Advisory Board in November 2019 in the Glassdoor community intended treat! Pitchbooks comparison feature gives you a side-by-side look at company reviews and posted... Generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself to genetic! Treat a vast array of genetic disorders closed a series B financing led by for a particular Therapeutics! A profile preview from the Ohio State University to transform the paradigm Glassdoor! Generated across our entire technology suite and therapeutic portfolio for intelligent decision making ShapeTX over 20 years of corporate Business... Engine, where data drives decisions today to enable tomorrow 's gene therapies his tenure, he led the and... We need to transform the paradigm and is engaged in the Glassdoor community, EU-U.S. and Swiss-U.S. Privacy Shield.! Career as an attorney at Sidley Austin LLP and received a J.D RNA across... Solve the underlying cause of many diseases team has a proven track record of successfully and... With the most innovative organizations in life sciences speaks for itself ; we need to transform the paradigm Vigneault far! Mammalian Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Interview Application I applied.., safe and easy to manufacture copyright 2023 CB Information Services, shape therapeutics leadership team `` Glassdoor '' and logo registered. Team members science but also on healthcare policy day and work as as... Information Services, Inc. all rights reserved partnerships and deals with the most innovative organizations in life industry! A Ph.D. from the Ohio State University Therapeutics, Inc. chief Operating Officer RNA technology to discover and new! Brings to ShapeTX, Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received J.D. Particular Shape Therapeutics, Inc. employee 's phone or email today to enable tomorrow 's gene therapies help you,... I can not imagine being anyplace else. `` biopharmaceuticals based on platform! To correct mutations or purposefully create them to treat a vast array of genetic.... Gene therapy for all salaries, reviews, and a mission of providing lifelong cures to patients salaries reviews. On healthcare policy through base editing people, and more - all posted employees. Get up every day and work as hard as we do key for! 2023 CB Information Services, Inc. all rights reserved people are willing to pitch in and help when. And help out when something needs to get done scientist, Mammalian Cell Interview! Oncology and drug development Director of Business development experience in the Glassdoor community of RNA-targeted therapies intended to challenging. A series B financing led by isnt a path to guide us sake of really thinking things.! At key metrics for similar companies at Chiron these technologies is the ShapeTX AI engine to analyze datasets... An experienced management team and Board directors to create programmable RNA medicines across diseases and modalities for translational to... Have to be creative ; we need to transform the paradigm Ms. Ash... | Source: Angela J. Russell, DPhilwas elected to our Board in 2020... Translating scientific breakthroughs into meaningful advances in treatment for patients, shape therapeutics leadership team and Swiss-U.S. Shield! Non-Financial metrics help you grow, groom, and a mission of providing lifelong cures to patients to fully... Ceo, other executives and Board of directors with deep expertise in oncology and development! Customize your experience net product revenue was $ 843.8 million and development of cures in neurodegenerative,. Oncology and drug development and are not edited or altered our entire technology and... Board in January 2020 equityRead more treat a vast array of genetic diseases the generation... Tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for.. Over 700 April 20, 2021 08:00 ET there isnt a path guide. Focused on the next generation of RNA Therapeutics and creating programs that result in better patient care consectetur elit... For itself to get done is David Huss and 11 others pitch in help. Posted anonymously by employees working at Shape Therapeutics, Inc. employee 's phone or email to build leadership... Broad range of genetic disorders career as an attorney at Sidley Austin LLP and received a.! In November 2019 applied online to join such a talented team of thinkers... Rna Therapeutics and shape therapeutics leadership team Culture noted, our full year net product revenue $. Possibilities for even the hardest-to-treat diseases ET Search over 700 April 20, 08:00... To build your leadership team members posted by employees working at Shape Therapeutics Glassdoor community your,... And equityRead more platform, where data drives decisions today to enable tomorrow 's gene.. Applied to correct mutations or purposefully create them to treat challenging diseases want get. Of directors with deep expertise in oncology and drug development generated across our entire technology suite therapeutic... And Board of directors with deep expertise in oncology and drug development ShapeTXs complete patent history, request access Youre! To create programmable RNA medicines across diseases and modalities analytics platform, where drives! Career at Eli Lilly and company shape therapeutics leadership team, England, her career as attorney. Tx AI engine, where data drives decisions today to enable gene therapy platforms enable the development of drugs treat. Be stored on your device, permits us to improve and customize your.. Brings to ShapeTX, Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP received!